<DOC>
	<DOCNO>NCT02144714</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics , safety , tolerability , immunogenicity SB5 Humira ( EU source Humira® US source Humira® ) healthy subject .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability Immunogenicity Study SB5 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy subject Have body mass index 20.0 29.9 kg/m² , inclusive . History and/or current presence clinical significant atopic allergy , hypersensitivity allergic reaction , also include know suspected clinically relevant drug hypersensitivity component test reference investigational product formulation comparable drug Active latent Tuberculosis history Tuberculosis History invasive systemic fungal infection opportunistic infection Systemic local infection , know risk develop sepsis and/or know active inflammatory process Serious infection associate hospitalisation and/or require intravenous antibiotic History and/or current cardiac disease Have receive live vaccine ( ) within 4 week prior Screening require live vaccine ( ) Screening final study visit Intake medication halflife &gt; 24 h within 4 week 10 halflives medication prior investigational product administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>